Hikma Gets $535m Off BI's Roxane Over Rebate Discrepancy
This article was originally published in Scrip
Executive Summary
"A very good deal that just got a little sweeter," is how Hikma CEO Said Darwazah described the $535m purchase price reduction of Roxane Laboratories Inc. from Boehringer Ingelheim. The discount was result of "new information" from BI in relation to Roxane's financial performance in 2015, specifically higher than expected rebates offered by Roxane.
You may also be interested in...
Hikma Set To Buy Back £295m In Shares
Boehringer Ingelheim, which holds a 16.4% share of Hikma along with voting rights, is ready to exit the company altogether as Hikma decides to buy back £295m worth of shares. Hikma has invited new investors, expressing confidence in its future plans.
Hikma Hit By Approval Delays, But Advair Diskus Generic Expected Next Year
Jordan's Hikma claims to be a more balanced generics company after the Roxane acquisition, and expects 2017 approval of an Advair Diskus generic, but delays in US generic approvals held back profits in the 2016 first half.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.